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pleteness of revascularization, and long-term outcome remain
to be proved. In the meantime, complications of this proce-
dure should be studied to allow adequate assessment of the
risk involved.
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SHORT-TERM EFFECT OF CYCLOSPORINE ON CIRCULATING ADRENOMEDULLIN AFTER HEART
TRANSPLANTATION
Bernard Geny, MD, PhD, Hélène Hardy, Eliane Lampert, MD, Anne Charloux, MD, Arnaud Charpentier, MD, Jean Lonsdorfer,
MD, Pascal Haberey, MD, and François Piquard, PhD, Strasbourg, France
Adrenomedullin (ADM) is a newly discovered potent
endogenous vasorelaxing and natriuretic peptide produced by
vascular smooth muscle and endothelial cells.1 Secreted by
the failing human heart in proportion to the severity of the
disease, ADM has been proposed to oppose the local and cir-
culating vasoconstrictive and sodium-retaining factors during
heart disease.2
Cardiac transplantation, an important surgical treatment for
end-stage heart failure, partially normalizes the neurohu-
moral activation, but heart transplant recipients generally
have hypertension and body fluid volume expansion. This
may explain why both cardiac hormones, atrial and brain natri-
uretic peptides, remain elevated after heart transplantation.3
Consistently, ADM has recently been reported to be elevated
in heart transplant recipients in relation to cyclosporine
(CsA) therapy (INN: ciclosporin), suggesting that ADM
might be a compensatory mechanism to offset further CsA-
induced development of cardiac or renal dysfunction.4
However, whether CsA acutely increases the third cardiac
hormone, ADM, in heart transplant recipients remains
unknown.
Methods and results. Six heart transplant recipients gave
informed consent and participated in the study, which was
approved by the institutional review board for human studies.
Resting values of plasma ADM, CsA, and creatinine, together
with systemic blood pressure, were determined with the
patient in the supine position, and the time courses of both
plasma ADM and CsA were obtained simultaneously during
the 7 hours after oral CsA administration (125 mg twice a
day). Plasma ADM concentration was determined by
radioimmunoassay with kits from Peninsula Laboratories
(Belmont, Calif), after extraction by Sep-Pak C18 cartridges
(Waters Corporation, Milford, Mass.). Total blood cyclo-
sporinemia was determined by immunoenzymatic assay
using kits from Behring Diagnostics Inc (Cupertino, Calif).
Heart transplant recipients were 47 ± 4 (mean ± SEM) years
old, weighed 70 ± 3 kg, and the delay since transplantation was
44 ± 9 months. Systolic and diastolic blood pressures were 157
± 9 and 98 ± 4 mm Hg, respectively, and serum creatinine con-
centration was 108 ± 7 m mol/L. Circulating ADM was higher
than control values (110 ± 17 vs 20 ± 3 pmol/L in heart trans-
plant recipients and control subjects, respectively; analysis of
variance, P < .0001) and tended to correlate positively with
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CsA through levels (r = 0.79, P = .059). No relationship was
observed between ADM and serum creatinine or blood pres-
sure. Fig 1 shows the simultaneous time course of plasma
ADM and CsA. CsA concentrations increased significantly,
peaked 90 minutes after drug administration (from 132 ± 17 to
783 ± 155 m g/L, P = .002), and returned near baseline value 7
hours later. However, interestingly, plasma ADM concentration
failed to change significantly after CsA administration.
Discussion. Confirming the elevation of circulating ADM
after heart transplantation in relation to CsA therapy, this
study demonstrates for the first time the lack of short-term
CsA-induced ADM increase in heart transplant recipients.
Although a decreased ADM renal clearance may participate
in ADM elevation, the very mild degree of renal impairment
generally observed after heart transplantation is unlikely to
participate significantly in ADM increase in heart transplant
recipients.2,4 Accordingly, no correlation was observed be-
tween circulating ADM and serum creatinine in our patients.
Thus an increased secretion and release may explain ADM
elevation after heart transplantation. Particularly, and consis-
tently with a positive relationship between CsA trough levels
and circulating ADM, it has been proposed that CsA may
enhance ADM release from vascular endothelial and smooth
muscle cells in heart transplant recipients.4 To investigate
whether this is a short-term effect of CsA, we monitored both
cyclosporinemia and ADM during the 7 hours after oral CsA
administration. This follow-up period appears long enough
because peak CsA level and maximal acute nephrotoxic
effect of CsA occur about 2 and 6 hours, respectively, after
CsA administration. The results show that, although CsA con-
centrations were greatly modified, no simultaneous change in
circulating ADM level was observed.
These data support the hypothesis that clinically relevant
CsA therapy does not acutely increase ADM in heart trans-
plant recipients. Furthermore, inasmuch as ADM increases
local blood flow in heart and kidneys and may be involved in
the defense mechanisms against further vascular resistance
increase in heart transplant recipients,4,5 it is possible that the
low-dose CsA commonly used in stable heart transplant
recipients may not significantly reduce renal or other local
circulations. Further studies will be useful to determine
whether increased ADM counteracts the long-term deleteri-
ous effects of CsA after cardiac transplantation.
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Fig 1. Time course of plasma cyclosporinemia and ADM
concentrations (means ± SEM) before (time 0) and after an
acute administration of CsA. Differences between means
were obtained by 1-way analysis of variance with repeated
measures on time. When probability was lower than .05, pair-
wise comparisons with values at “time 0” were assessed by
Tukey’s test: *P < .01.
